Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02283762 |
|
Recruitment Status :
Completed
First Posted : November 5, 2014
Results First Posted : January 25, 2019
Last Update Posted : February 5, 2020
|
Sponsor:
Bayer
Information provided by (Responsible Party):
Bayer
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
To investigate if Riociguat is effective in the treatment of systemic sclerosis
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Scleroderma, Systemic | Drug: Riociguat (Adempas, BAY63-2521) Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 121 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) |
| Actual Study Start Date : | January 15, 2015 |
| Actual Primary Completion Date : | December 15, 2017 |
| Actual Study Completion Date : | March 28, 2019 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Systemic scleroderma
MedlinePlus related topics:
Scleroderma
Drug Information available for:
Riociguat
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Riociguat
Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
|
Drug: Riociguat (Adempas, BAY63-2521)
Starting dose 0.5 mg TID, increase by 0.5 mg every 2 weeks until highest possible dose of 2.5 mg TID |
|
Placebo Comparator: Placebo
Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
|
Drug: Placebo
Sham-titration |
Primary Outcome Measures :
- Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52 [ Time Frame: Baseline to week 52 ]The mRSS is a validated physical examination method for estimating skin thickness. It correlates with biopsy measures of collagen in the dermis and reflects prognosis and visceral involvement, especially in early disease. It is scored on 0 (normal) to 3+ (severe induration) ordinal scales over 17 body areas, with a maximum score of 51 (higher score means worse situation) and is used to categorize severity of SSc. A decrease in the mean change of mRSS shows mRSS improved.
Secondary Outcome Measures :
- CRISS (American College of Rheumatology Composite Response Index for Clinical Trials) at Week 52 Reported as Number of Participants With a CRISS Probability >=0.60 or <0.60 From Baseline to Week 52 [ Time Frame: Week 52 ]CRISS forms a composite response index consisting of SSc-related organ involvement and the following five variables: mRSS, FVC percent predicted, physician's and patient's global assessments, and HAQ-DI score (from SHAQ patient-reported outcome). The resulting index is a 2-step process that captures clinically meaningful worsening of internal organ involvement and the core variables that show change. Patients for whom the predicted CRISS probability was ≥ 0.60 were considered improved, while patients for whom the predicted probability was < 0.60 were considered not improved.
- Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score to Week 52 [ Time Frame: Baseline to week 52 ]The HAQ-DI is a composite measure from which a 'Standard Disability Index' score can be computed to assess a patient's disability level. Generally, a score of 0-1 represents mild to moderate difficulty, 1-2 moderate to severe disability and 2-3 severe to very severe disability. The HAQ-DI comprises 20 items that assess patient abilities across 8 functional activities: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item is rated on a 4-point scale: 0=Without ANY difficulty, 1=With SOME difficulty, 2=With MUCH difficulty, 3=UNABLE to do. The 8 scores of the 8 sections are summed and divided by 8. In the event that one section is not completed by a subject then the summed score would be divided by 7. The final overall HAQ-DI score ranges from 0 to 3 and positive change indicates worse health-related quality of life (HRQoL).
- Change From Baseline in Patient's Global Assessment Score to Week 52 [ Time Frame: Baseline to week 52 ]The patient's global assessments (a self-report) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the patient's global assessments score indicates worsening.
- Change From Baseline in Physician's Global Assessment Score to Week 52 [ Time Frame: Baseline to week 52 ]The physician's global assessments (reported by the physician) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the physician's global assessments score indicates worsening.
- Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted to Week 52 [ Time Frame: Baseline to week 52 ]Negative change in FVC percent predicted indicates worsening.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Men or women aged 18 years and older
- Systemic sclerosis, as defined by ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) 2013 criteria
- dcSSc (diffuse cutaneous systemic sclerosis) according to the LeRoy criteria, ie, skin fibrosis proximal to the elbows and knees in addition to acral fibrosis
- Disease duration of ≤ 18 months (defined as time from the first non-Raynaud's phenomenon manifestation)
- ≥ 10 and ≤ 22 mRSS (modified Rodnan skin score) units at the screening visit
- FVC (forced vital capacity) ≥ 45% of predicted at screening
- DLCO (diffusion capacity of the lung for carbon monoxide) ≥ 40% of predicted (hemoglobin-corrected) at screening
- Negative serum pregnancy test in a woman of childbearing potential at the screening visit
- Women of childbearing potential must agree to use adequate contraception when sexually active. "Adequate contraception" is defined as any combination of at least 2 effective methods of birth control, of which at least 1 is a physical barrier (e.g. condom with hormonal contraception like implants or combined oral contraceptives, condom with intrauterine devices). This applies since signing of the informed consent form until 30 (+5) days after the last study drug administration.
Exclusion Criteria:
- Limited cutaneous SSc (systemic sclerosis) at screening
- Major surgery (including joint surgery) within 8 weeks prior to screening
- Hepatic insufficiency classified as Child-Pugh C
- Patients with isolated AST or ALT >3xULN or bilirubin >2xULN can be included in the trial under the condition of additional monitoring during the trial
- Estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m^2 (Modification of Diet in Renal Disease formula) or on dialysis at the screening visit. Patients entering the trial with eGFR 15-29 mL/min/1.73 m^2 will be undergo additional monitoring of renal function
- Any prior history of renal crisis
- Sitting SBP (systolic blood pressure) < 95 mmHg at the screening visit
- Sitting heart rate < 50 beats per minute (BPM) at the screening visit
- Left ventricular ejection fraction < 40% prior to screening
- Any form of pulmonary hypertension as determined by right heart catheterization
- Pulmonary disease with FVC < 45% of predicted or DLCO (hemoglobin-corrected) < 40% of predicted at screening
- Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization
- Not permitted prior and concomitant medication
- Pregnant or breast feeding women
- Women of childbearing potential not willing to use adequate contraception and not willing to agree to 4-weekly pregnancy testing from Visit 1 (first administration of study drug) onwards until 30 (+5) days after last study drug intake.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02283762
Locations
Show 59 study locations
Sponsors and Collaborators
Bayer
Investigators
| Study Director: | Bayer Study Director | Bayer |
Study Documents (Full-Text)
Documents provided by Bayer:
Documents provided by Bayer:
Study Protocol [PDF] April 17, 2018
Statistical Analysis Plan [PDF] March 6, 2019
Additional Information:
Publications:
Publications:
| Responsible Party: | Bayer |
| ClinicalTrials.gov Identifier: | NCT02283762 |
| Other Study ID Numbers: |
16277 2014-001353-16 ( EudraCT Number ) |
| First Posted: | November 5, 2014 Key Record Dates |
| Results First Posted: | January 25, 2019 |
| Last Update Posted: | February 5, 2020 |
| Last Verified: | January 2020 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Scleroderma, Systemic Scleroderma, Diffuse Connective Tissue Diseases Skin Diseases |
Riociguat Enzyme Activators Molecular Mechanisms of Pharmacological Action |